Infection and disease caused by the human cytomegalovirus (CMV) remains a challenge in transplant recipients. Two new drugs, letermovir (Prevymis, Merck) and maribavir (Livtencity, Takeda) are now available for prevention and treatment, respectively, of CMV disease. This article reviews the clinical role of these drugs.
Overview
Prevention and treatment of CMV disease is a fundamental part of supportive care for recipients of hematopoietic stem cell transplant (HSCT)